ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Trend
+37.3% vs SMA 50 · +80.6% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $10000 $10000–$10000 | — | -$1.74 | — | ±2% | Moderate3 |
FY2026(current) | $10000 $10000–$10000 | ▲ +0.0% | -$2.02 | — | ±18% | Moderate4 |
FY2027 | $10000 $10000–$10000 | ▲ +0.0% | -$2.65 | — | — | High5 |
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.